

RESEARCH ARTICLE

Genome-wide association study of abdominal MRI-measured visceral fat: The multiethnic cohort adiposity phenotype study

Samantha A. Streicher^{1*}, Unhee Lim¹, S. Lani Park¹, Yuqing Li², Xin Sheng³, Victor Hom³, Lucy Xia³, Loreall Pooler³, John Shepherd¹, Lenora W. M. Loo¹, Thomas Ernst⁴, Steven Buchthal¹, Adrian A. Franke¹, Maarit Tiirikainen¹, Lynne R. Wilkens¹, Christopher A. Haiman³, Daniel O. Stram³, Iona Cheng², Loïc Le Marchand¹

1 University of Hawaii Cancer Center, University of Hawaii at Mānoa, Honolulu, Hawaii, United States of America, **2** Department of Epidemiology and Biostatistics, University of California–San Francisco, San Francisco, California, United States of America, **3** Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America, **4** University of Maryland School of Medicine, Baltimore, Maryland, United States of America

* sstreicher@cc.hawaii.edu



OPEN ACCESS

Citation: Streicher SA, Lim U, Park SL, Li Y, Sheng X, Hom V, et al. (2023) Genome-wide association study of abdominal MRI-measured visceral fat: The multiethnic cohort adiposity phenotype study. PLoS ONE 18(1): e0279932. <https://doi.org/10.1371/journal.pone.0279932>

Editor: Nicholette D. Palmer, Wake Forest School of Medicine, UNITED STATES

Received: May 12, 2022

Accepted: December 16, 2022

Published: January 6, 2023

Copyright: © 2023 Streicher et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: The Multiethnic Cohort Adiposity phenotype Study (MEC-APS) data set is available from the data base of genotypes and phenotypes (dbGaP) (accession number phs001689.v1.p1). The URL is https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001689.v1.p1.

Funding: This work was supported by the U.S. National Institutes of Health (NIH), National Cancer Institute (NCI) for the Adiposity Phenotype Study (P01 CA168530 to L.L.M.) and Multiethnic Cohort

Abstract

Few studies have explored the genetic underpinnings of intra-abdominal visceral fat deposition, which varies substantially by sex and race/ethnicity. Among 1,787 participants in the Multiethnic Cohort (MEC)-Adiposity Phenotype Study (MEC-APS), we conducted a genome-wide association study (GWAS) of the percent visceral adiposity tissue (VAT) area out of the overall abdominal area, averaged across L1-L5 (%VAT), measured by abdominal magnetic resonance imaging (MRI). A genome-wide significant signal was found on chromosome 2q14.3 in the sex-combined GWAS (lead variant rs79837492: Beta per effect allele = -4.76; $P = 2.62 \times 10^{-8}$) and in the male-only GWAS (lead variant rs2968545: (Beta = -6.50; $P = 1.09 \times 10^{-9}$), and one suggestive variant was found at 13q12.11 in the female-only GWAS (rs79926925: Beta = 6.95; $P = 8.15 \times 10^{-8}$). The negatively associated variants were most common in European Americans (T allele of rs79837492; 5%) and African Americans (C allele of rs2968545; 5%) and not observed in Japanese Americans, whereas the positively associated variant was most common in Japanese Americans (C allele of rs79926925, 5%), which was all consistent with the racial/ethnic %VAT differences. In a validation step among UK Biobank participants ($N = 23,699$ of mainly British and Irish ancestry) with MRI-based VAT volume, both rs79837492 (Beta = -0.026, $P = 0.019$) and rs2968545 (Beta = -0.028, $P = 0.010$) were significantly associated in men only ($n = 11,524$). In the MEC-APS, the association between rs79926925 and plasma sex hormone binding globulin levels reached statistical significance in females, but not in males, with adjustment for total adiposity (Beta = -0.24; $P = 0.028$), on the log scale. Rs79837492 and rs2968545 are located in intron 5 of *CNTNAP5*, and rs79926925, in an intergenic region between *GJB6* and *CRYL1*. These novel findings differing by sex and racial/ethnic group warrant replication in additional diverse studies with direct visceral fat measurements.

Study (U01 CA164973 to L.L.M., L.R.W., and C.A.H.); NCI (P30 CA071789 to University of Hawaii Cancer Center Shared Resources for Biostatistics, Analytical Biochemistry, Genomics, and Nutrition Support services); and the National Center for Advancing Translational Science, NIH, for recruitment activities at USC (UL1TR000130 to Southern California Clinical and Translational Science Institute). S.A.S. was funded by a NCI training grant (T32 CA229100). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Excess body fatness is an established risk factor for type 2 diabetes, cardiovascular disease, and multiple common cancers [1, 2]. Abdominal visceral adipose tissue (VAT) has been shown to be more metabolically active compared to fat stored in other areas of the body, such as subcutaneous adipose tissue (SAT) [3, 4]. Recent studies have shown strong associations between VAT and type 2 diabetes, cardiovascular disease, and breast cancer [3, 5, 6]. VAT has greater metabolic activity and direct access to the portal circulation, which promotes an abnormal metabolic profile (i.e. circulating levels of high insulin, leptin, sex steroids, adiponectin, C-reactive protein) [7–10].

It is well established that the absolute or relative size of VAT differs substantially by sex and race/ethnicity [11, 12]. In the Multiethnic Cohort-Adiposity Phenotype Study (MEC-APS) (N = 1,861), we found that men had substantially more magnetic resonance imaging (MRI)-measured abdominal VAT compared to women, even after adjusting for age, height, and total adiposity [12]. Differences in sex-specific fat accumulation become evident at the onset of puberty with women preferentially accumulating fat in the gluteofemoral region and men accumulating more fat as visceral fat in the abdominal region [13]. In women, when estrogen levels decrease during their menopausal transition, fat redistributes away from the gluteofemoral region towards more visceral fat [13]. In addition, results from an analysis of a large extended pedigree from a genetic isolate in the Netherlands showed that genes account for significantly more variance for waist circumference, hip circumference, and waist to hip ratio in women (mean age = 47.5 years) than in men (mean age = 48.5) [14]. Different genes were found contributing to the variance of the waist to hip ratio in men compared to women, and common genes accounted for a larger magnitude of the variance for waist and hip circumference in women than men [14].

In the MEC-APS, the amount of MRI-measured VAT also significantly differed among the five race/ethnicities (African American, European American, Japanese American, Latino, and Native Hawaiian), even after adjusting for age, height, and total adiposity [12]. Japanese Americans had the largest VAT area in both males and females (234 cm² and 176 cm², respectively) and African Americans had the smallest VAT area in both males and females (161 cm² and 102 cm², respectively), adjusted for total adiposity [12]. In another study in the MEC, for similar body mass index (BMI), Japanese American women, compared to White women, had a significantly higher MRI-measured VAT area out of the abdominal area across L4-L5 (23.9% vs. 18.5%, respectively), after adjusting for age and total adiposity [15].

Accounting for possible sex-differences in genetic susceptibility variants, several studies have conducted sex-stratified genome-wide association studies (GWAS) of computed tomography (CT)- or MRI-measured VAT [16–20]. Two genome-wide significant variants (rs2842895 and rs2185405) were associated with abdominal VAT together in males and females; another two variants (rs11118316 and rs7374732) were associated with the abdominal VAT to SAT ratio together in males and females; three novel variants (rs1659258, rs10060123, and rs17104731) were associated with abdominal VAT in females-only; and two variants (rs12657394 and rs1002945) were associated with abdominal VAT in males-only [16–20]. An additional study using 396,220 UK Biobank participants predicted VAT mass from dual energy X-ray absorptiometry (DXA) and found 101 variants associated with predicted VAT mass at genome-wide significance in males and females, and one additional variant in males [21]. However, these studies have mostly been in individuals of European ancestry.

Recognizing the need to further elucidate the genetic determinants of VAT variation by sex and race/ethnicity based on accurate measurements, we performed a sex-combined and sex-specific GWAS study of visceral adiposity, evaluated by MRI in the MEC-APS. We, then,

examined variants that were genome-wide significant ($P < 5 \times 10^{-8}$) and suggestive ($P < 10^{-7}$) for association with obesity-related biomarkers in MEC-APS and for replication with VAT in the UK Biobank data.

Methods

The MEC-APS

The MEC is an ongoing prospective study in Hawaii and Los Angeles that was established to examine the association of lifestyle and genetic risk factors with cancer and other chronic diseases. In 1993–1996, 96,810 men and 118,441 women between 45 and 75 years of age were recruited. Participants are mainly from five main racial/ethnic groups (African American, European American, Japanese American, Latino, Native Hawaiian) [22]. The MEC-APS was conducted in 2013–2016 among a subset of MEC participants to identify predictors of body fat distribution and risk factors for obesity-related cancers, as described previously [12]. Briefly, the MEC-APS is a cross-sectional study that recruited 1,861 healthy, nonsmoking men and women between 60 and 77 years of age with body mass index (BMI) between 17.1–46.2 kg/m². MEC participants were selected for the study using a stratified sampling by sex, race/ethnicity, and six BMI categories. Exclusion criteria included reported BMI outside the range of 18.5–40 kg/m², smoking in the past 2 years, soft or metal body implants or amputation, insulin or thyroid medications, and serious medical conditions (e.g., dialysis, chronic hepatitis, previous cancer diagnosis). Study participants underwent an abdominal MRI and a whole-body dual energy X-ray absorptiometry (DXA) scan, provided a blood sample after an overnight fast, completed a self-administered questionnaire, and underwent anthropometric measurements [12]. All MEC-APS participants provided written informed consent and the study was approved by the institutional review boards (IRBs) at the University of Hawaii (UH) (CHS-#17200), University of Southern California (USC) (#HS-12-00623), and University of California, San Francisco (UCSF) (#17–23399) in agreement with the 1975 Helsinki Declaration. Seventy-four participants were excluded because of missing visceral fat value based on an invalid scan due to implants, motion artifacts, or presence of a visceral mass, leaving 1,787 MEC-APS participants in the final study population.

Anthropometric and body composition assessment

Trained technicians obtained measurements of height, weight, circumferences of the waist and hip, and chest depth [12]. 3T MRI scanners (Siemens TIM Trio at UH and General Electric HDx at USC) were used. An abdominal scan was acquired to quantify VAT areas (square centimeters) at 4 intervertebral segments of the intra-abdominal cavity (L1–L2, L2–L3, L3–L4, L4–L5) using an axial gradient-echo sequence with breath holds [12]. The average VAT across the segments L1–L5 was used in analysis. Whole-body composition, including total fat mass and muscle mass, was determined by a DXA scan (Hologic Discovery A fan-beam densitometer at UH and USC, Bedford, MA) [12]. Extensive details regarding the imaging protocol, as well as quality control calibration and estimation of VAT and SAT area were previously published [12].

Genotyping, quality control, and imputation

Genotyping and imputation for the MEC-APS participants have been described previously [23]. Briefly, DNA extraction from buffy coat was performed using the Qiagen QIAMP DNA kit (Qiagen Inc., Valencia, CA). DNA samples were genotyped on the Illumina expanded multi-ethnic genotyping array (MEGA^{EX}) platform, which provides a large coverage of

variants across the genome for diverse ancestral populations [24]. Variants were removed if they had a call rate <95%, replicate concordance <100% based on 39 QC replicate samples, or poor clustering after visual inspection. Prior to imputation, monomorphic variants, variants with a call rate <98%, variants with estimated MAF (minor allele frequency) that deviated by $\geq 20\%$ in comparison to the corresponding ancestral group in the 1000 Genomes Project Phase 3, discordance in reported vs. genotyped sex, and insertions/deletions that were not included in the Haplotype Reference Consortium (HRC), were removed. From an initial 2,036,060 genotyped variants, 1,417,570 were available for imputation. Phasing using Eagle v2.4 and genotype imputation using Minimac v4 were performed on the University of Michigan Imputation Server with the HRC vr1.1 2016 reference panel [25, 26]. After genotype imputation for MEC-APS participants, variants with an imputation quality score of < 0.4, multiallelic variants, variants with MAF < 0.01, or monomorphic variants, were excluded from all subsequent analyses. In total, 9,542,479 genotyped and imputed variants remained after post-imputation filtering. Principal components for ancestry adjustment were calculated with 16,621 post-quality control genotyped race/ethnic specific pruned single nucleotide polymorphisms using EIGENSOFT v7 [27]. A quantile–quantile plot of GWAS P-values indicated appropriate control of type I error for the total population, males, and females, with a genomic inflation (λ) value of 0.98, 0.98, and 0.96, respectively (S1A–S1C Fig).

Obesity-related biomarkers

Selected blood biomarkers were assayed because of their reported associations with obesity-caused metabolic, hormonal, and inflammation dysfunctions [5]. Fasting blood samples were collected at the time of body composition measurement, processed into components, and stored at -80°C [5]. Plasma or serum concentrations were determined for circulating levels of high density lipoprotein (HDL) (mg/dL) (N = 1,822), total cholesterol (mg/dL) (N = 1,823), glucose (mg/dL) (N = 1,821), C-reactive protein (CRP) (mg/dL) (N = 1,823), insulin (microU/mL) (N = 1,823), sex-hormone binding globulin (SHBG) (nmol/L) (N = 1,816), triglycerides (mg/dL) (N = 1,823), and alanine aminotransferase (ALT) (U/L) (N = 1,823) [5]. HOMA-IR (N = 1,821) and HOMA-beta (N = 1,810) were derived from fasting glucose and insulin values [5, 28, 29], and low-density lipoprotein (LDL; N = 1,817) cholesterol was derived from the Friedewald equation using total and HDL cholesterol values and a valid range of triglyceride concentrations [30].

UK Biobank

The UK Biobank participants, genotyping, imputation, and imaging have been described in detail previously [31–33]. Briefly, the UK Biobank recruited over 500,000 individuals, aged 40–69 years, mainly of white British ancestry from across the UK during 2006–2010 [31]. Participants were interviewed about lifestyle and disease history and underwent a physical examination that included measurements on weight, height, and waist and hip circumference [31]. Genotyping for UK Biobank participants was done with two custom genotyping arrays, UK BiLEVE and Axiom [32]. The UK10K and 1000 Genomes Phase 3 reference panels were used as reference panels for imputation [25, 32, 34]. Between 2014 and 2020 a subset of 43,521 UK Biobank participants underwent MRI imaging. VAT volume (data field: 22407), measured by summing the VAT area across images, was quantified by abdominal MRI in a subset of 25,103 participants using a Siemens 1.5 T MAGNETOM Aera scanner (Siemens, Erlangen, Germany) with the dual-echo Dixon Vibe protocol covering neck to knees [33, 35]. This analysis of data from the UK Biobank was performed under UK Biobank application #16447.

Statistical analysis

Descriptive characteristics were examined in the overall study population, in males, and in females, by race/ethnicity (African American, European American, Japanese American, Latino, Native Hawaiian) using SAS v.9.4.

The median percent VAT area out of the overall abdominal area, averaged across L1-L5 (% VAT) presented a greater contrast across the five race/ethnic groups compared to absolute VAT area, averaged over L1-L5 (using Mass-Whitney U test; $P = 2.3 \times 10^{-31}$ vs. $P = 2.3 \times 10^{-14}$, respectively); therefore, %VAT was used for the GWAS outcome. Variants (as imputed dosages) were tested for associations among sex-combined ($N = 1,787$) MEC-APS participants using linear regression of %VAT on SNPs using additive genetic models, adjusted for age, sex, and principal components 1–4. Sex-specific (male $n = 878$, female $n = 909$) GWAS were also performed using linear regressions of %VAT, adjusted for age and sex-specific principal components 1–4 with additive genetic models. SNP associations were considered statistically significant at the genome-wide significance threshold of $P < 5 \times 10^{-8}$, and as suggestive at $P < 10^{-7}$. To evaluate independent variant effects, conditional analysis was then conducted that included variants from the same chromosome signal with $P < 10^{-7}$. Since %VAT was correlated, albeit weakly, with total fat mass ($r = 0.12$), its associations with the independent lead variants were rerun with additional adjustment for total adiposity. All analyses were done in PLINK v2.0. The %VAT outcome was not transformed because the non-transformed error residuals were normally distributed and a quantile-quantile plot of GWAS P-values of variant associations indicated appropriate control of type I errors with genomic inflation (λ) value for GWAS was close to 1 (S1A–S1C Fig) [36].

Lead variants associated with %VAT from the sex-combined and sex-specific GWAS were also assessed for relationships within each MEC-APS race/ethnic group (African American $n = 301$, European American $n = 401$, Japanese American $n = 428$, Latino $n = 372$, Native Hawaiian $n = 285$) using linear regression and adjusted for age, sex (for variants associated with %VAT in sex-combined data), and race/ethnic-specific principal components in PLINK v2.0.

Okinawan Americans were genetically distinguished from mainland Japanese Americans among 428 Japanese Americans in the MEC-APS using principal component analysis. The principal component 1 vs. principal component 2 plot allowed for visualization of the spread of Japanese Americans (S2 Fig). Identification of Okinawan Americans was based on previous principal component analysis plots that identified Okinawans and where subject clusters thinned [37]. Cross-check of participants in the Okinawan cluster with Okinawan last names indicated that the majority of the last names in the Okinawan cluster were of Okinawan origin. There were 72 genetically identified Okinawan Americans, 27 part-Okinawan and part-mainland Japanese Americans, and 333 mainland Japanese Americans (S2 Fig). Medians and P-values of % VAT between Okinawan Americans and mainland Japanese were calculated using SAS v.9.4.

Lead genetic variants with %VAT were also examined for association with obesity-related blood biomarkers (HDL, LDL, total cholesterol, glucose, insulin, HOMA-beta, HOMA-IR, CRP, SHBG, triglycerides, and ALT) among over 1,800 MEC-APS participants [5] using linear regression of each log-transformed biomarker on each lead genetic variant adjusted for age, sex (for variants associated with %VAT in sex-combined data), total fat mass, and principal components 1–4 (see above in *Obesity-related biomarkers* for exact number of participants analyzed for each biomarker) using R v3.6.1. The same lead genetic variants were also assessed for replication in the UK Biobank using linear regression models of log-transformed VAT volume adjusted for BMI, age, sex, and principal components 1–4 using PLINK v.2.0.

Results

The GWAS study population consisted of 1,787 MEC-APS participants (Table 1). The stratified recruitment into MEC-APS resulted in similar numbers of study participants across sex-race/ethnicity-BMI categories. The median overall age at clinic visit was 69.8 years. Across all race/ethnicities males had higher %VAT compared to females (Table 1). Overall, and in males and females, Japanese Americans (overall = 26.6%, male = 30.11%, female = 22.8%) had the highest % VAT, followed by Latinos (overall = 25.6%, males = 30.10%, females = 22.4%), Native Hawaiians (overall = 23.3%, males = 27.0%, females = 20.8%), and European Americans (overall = 28.8%, males = 26.8%, females = 18.7%). African Americans had the lowest %VAT overall (19.0%) and in males (30.11%) and females (16.6%) (Table 1).

In the sex-combined MEC-APS GWAS, there was a signal on chromosome 2q14.3, located in intron 5 of *CNTNAP5*, with 11 genome-wide significant variants and five suggestive variants ($P < 10^{-7}$), associated with %VAT (Figs 1A and 2A and Table 2A). The most significant association (rs79837492) was the lead variant in a conditional analysis that included these 16 variants with $P < 10^{-7}$. This 16-variant signal on chromosome 2q14.3 is located in intron 5 of *CNTNAP5* (Contactin Associated Protein Family Member 5). The T allele of the lead variant, rs79837492, was associated with a mean decrease of 4.76 in %VAT per effect allele ($P = 2.62 \times 10^{-8}$), independent of age, sex, and principal components (Table 2A). With additional adjustment for total fat mass, rs79837492 was associated with %VAT at $P = 2.50 \times 10^{-6}$ (Beta per effect allele = -3.74) (S1 Table). The variant T allele of rs79837492 was most common in European Americans (5%), present at lower frequency in African Americans (3%), Latinos (2%) and Native Hawaiians (1%) and not observed in Japanese Americans (Table 3A). The most significant association across race/ethnicities between rs79837492 and %VAT was in African Americans (Beta = -6.15; $P = 1.0 \times 10^{-4}$) with consistent effect estimates and directions of associations in the other non-monomorphic populations (Table 3A).

In the male-specific GWAS of %VAT, the signal on chromosome 2q14.3 gained magnitude and strength: all 16 significant or suggestive variants from the sex-combined GWAS were significant in men, with two additional significant variants (rs113164486 and rs76524201) and an additional suggestive variant (rs77919433) associated with %VAT (Figs 1B and 2B and Table 2B). The most significant association (rs2968545) was the lead variant in a conditional analysis that included the 19 variants from the chromosome 2q14.3 signal with $P < 10^{-7}$ in males. The variant C allele of the lead variant, rs2968545, was associated with a mean decrease of 6.5 per effect allele in %VAT ($P = 1.09 \times 10^{-9}$), independent of age and principal components (Table 2B). With additional adjustment for total fat mass, rs2968545 was associated with the %VAT at $P = 2.50 \times 10^{-6}$ (Beta = -3.74) (S1 Table). In males, the C allele of rs2968545 was most common in African Americans (11%), less common in European Americans (5%), present at low frequency in Latinos (1.8%) and Native Hawaiians (0.03%), and not observed in Japanese Americans (Table 3B). The most significant association across race/ethnicities among men between rs2968545 and %VAT was in European Americans (Beta = -9.10; $P = 4.69 \times 10^{-6}$) with consistent effect estimates and directions of associations in the other non-monomorphic populations (Table 3B).

None of the 19 variants identified in the male GWAS on chromosome 2 were associated with %VAT in females, but all betas were in the same direction (S2A and S3A Tables). In the female MEC-APS GWAS of %VAT, there was a suggestive association with rs79926925 and %VAT on chromosome 13q12.11 in an intergenic region between *GJB6* (Gap Junction Beta 6 or Connexin 30) and *CRYL1* (crystallin lambda 1). The variant C allele of rs79926925 on chromosome 13q12.11 was associated with a mean increase of 6.95 in %VAT ($P = 8.15 \times 10^{-8}$) independent of age and principal components (Fig 1C and Table 2C). With additional adjustment for

Table 1. Descriptive characteristics of MEC-APS subjects with valid visceral fat area and genotyping values, overall and by race/ethnicity (N = 1787)^a.


	Overall	African American	European American	Japanese American	Latino	Native Hawaiian
All, N (%)	1787	301 (16.7)	401 (22.4)	428 (24.0)	372 (20.8)	285 (15.9)
Age at clinic visit, years	69.1 (67.1, 71.3)	69.8 (67.9, 72.0)	68.6 (67.1, 70.9)	68.7 (66.8, 70.5)	69.7 (67.4, 72.1)	68.4 (66.5, 71.1)
Sex, n (%)						
Male	878 (49.1)	126 (41.9)	207 (51.6)	227 (53.0)	187 (50.2)	131 (46.0)
Female	909 (50.9)	174 (58.1)	194 (48.3)	201 (47.0)	185 (49.8)	154 (54.0)
Visceral fat to abdominal area ratio	23.5 (17.9, 29.9)	19.0 (14.9, 24.5)	21.7 (16.5, 28.2)	26.6 (20.2, 32.3)	25.6 (20.7, 26.4)	23.3 (18.1, 28.9)
Subcutaneous fat to abdominal area ratio	32.5 (25.9, 40.7)	40.1 (32.5, 47.4)	28.8 (23.2, 38.1)	28.1 (24.0, 35.1)	34.9 (27.1, 42.9)	34.5 (27.5, 40.3)
Visceral fat area (L1-L5), cm ²	157.4 (105.6, 215.0)	135.5 (94.6, 193.4)	141.2 (93.9, 204.7)	159.3 (104.4, 210.8)	188.9 (132.6, 248.1)	156.5 (107.8, 215.2)
Subcutaneous fat area (L1-L5), cm ²	211.6 (154.3, 282.4)	272.5 (205.8, 359.5)	191.1 (136.0, 267.8)	166.3 (130.0, 217.1)	236.4 (180.5, 312.7)	220.3 (172.0, 286.6)
Abdominal area (L1-L5), cm ²	658.8 (555.9, 770.1)	700.0 (587.6, 823.3)	649.8 (552.6, 759.7)	579.5 (502.9, 686.6)	708.2 (599.3, 812.6)	665.8 (566.9, 771.9)
Visceral fat area/subcutaneous fat area	0.74 (0.48, 1.15)	0.49 (0.34, 0.61)	0.71 (0.49, 0.88)	0.96 (0.62, 1.36)	0.80 (0.53, 1.22)	0.71 (0.50, 1.05)
Total fat mass, kg	24.2 (18.8, 29.9)	29.0 (24.0, 36.2)	22.3 (17.5, 27.6)	19.8 (16.3, 24.1)	27.9 (23.2, 33.2)	23.2 (19.5, 28.0)
Body mass index, kg/m ²	27.3 (24.4, 30.8)	28.9 (25.3, 32.2)	26.4 (23.5, 29.8)	25.9 (23.0, 28.9)	28.5 (25.7, 32.2)	28.2 (25.2, 31.7)
Men, n (%)	878 (49.1)	126 (14.3)	207 (23.6)	227 (25.8)	187 (21.3)	131 (14.9)
Age at clinic visit, years	69.2 (67.1, 71.4)	70.2 (67.8, 72.3)	68.3 (66.9, 70.8)	68.7 (66.8, 70.5)	69.7 (67.4, 72.3)	69.2 (66.8, 71.4)
Visceral fat to abdominal area ratio	28.1 (21.9, 33.2)	24.4 (19.8, 29.7)	26.8 (18.4, 32.2)	30.1 (24, 34.1)	30.1 (26, 35.4)	27 (20.8, 32.1)
Subcutaneous fat to abdominal area ratio	26.2 (22.3, 30.7)	31.2 (26.3, 36.9)	24.4 (21.1, 28.5)	24.1 (20.7, 27)	27.8 (23.9, 32.4)	27.4 (23.2, 31.5)
Visceral fat area (L1-L5), cm ²	198.6 (137.2, 254.4)	181 (134.1, 232.1)	187.9 (114.4, 248.7)	186.8 (130.2, 243.8)	236.8 (182.4, 283.2)	190.2 (133, 248.3)
Subcutaneous fat area (L1-L5), cm ²	178.4 (136.6, 230.9)	216.6 (169.4, 295.1)	167.9 (130.5, 211.1)	148.2 (113.7, 182.3)	203.1 (153.1, 256.7)	195.4 (145, 242.3)
Abdominal area (L1-L5), cm ²	688.2 (591.9, 798.5)	717.3 (642.5, 846.8)	683 (601.9, 777.5)	620.2 (519.3, 707.5)	742.8 (651.7, 842.9)	703.2 (598.4, 813.3)
Visceral fat area/subcutaneous fat area	1.1 (0.83, 1.5)	0.8 (0.6, 1.1)	1.1 (0.8, 1.5)	1.3 (1, 1.7)	1.2 (0.9, 1.6)	1.1 (0.8, 1.3)
Total fat mass, kg	22.1 (17.5, 27.1)	26.9 (22.7, 32.6)	20.5 (16.3, 25.5)	18.5 (15.1, 22.2)	26.1 (21.8, 30.5)	21.5 (17.9, 26.4)
Body mass index, kg/m ²	27.1 (24.8, 30.3)	28.3 (25.8, 31.1)	26.5 (24.1, 29.5)	26 (23.1, 28.8)	28.2 (26, 31.3)	28.2 (25.7, 31.4)
Women, n (%)	909 (50.9)	175 (19.3)	154 (16.9)	201 (22.1)	185 (20.3)	194 (21.3)
Age at clinic visit, years	69.0 (67.1, 71.2)	69.5 (67.9, 71.7)	69 (67.1, 70.9)	68.7 (66.8, 70.6)	69.5 (67.3, 71.9)	67.9 (66.1, 70.8)
Visceral fat to abdominal area ratio	20.1 (16.0, 24.5)	16.6 (13, 19.8)	18.7 (14.9, 22.7)	22.8 (18, 27.8)	22.4 (18.5, 25.2)	20.8 (16.8, 24.8)
Subcutaneous fat to abdominal area ratio	39.5 (33.9, 45.4)	45.5 (40.4, 50.7)	37.8 (30.1, 44.2)	35 (29.8, 39.1)	42.4 (37.3, 48)	38.9 (35.1, 44.1)
Visceral fat area (L1-L5), cm ²	128.9 (91.5, 170.9)	114.1 (82.9, 150.1)	118 (76.7, 162.6)	128.5 (92, 176.6)	145.7 (111.2, 190.3)	140.2 (97.1, 180.6)
Subcutaneous fat area (L1-L5), cm ²	246.7 (189.4, 316.1)	298.5 (229.4, 401.2)	239.6 (154.1, 294.1)	192.8 (154.9, 240.2)	287.3 (222.7, 366.5)	248.8 (206.9, 310.4)
Abdominal area (L1-L5), cm ²	622.9 (531.0, 736.9)	679.4 (556.8, 793.2)	642.6 (540.6, 730.2)	559 (483.1, 639.3)	677.1 (578.2, 785.1)	600.8 (488, 720.6)
Visceral fat area/subcutaneous fat area	0.51 (0.39, 0.68)	0.4 (0.3, 0.5)	0.5 (0.4, 0.7)	0.6 (0.5, 0.9)	0.5 (0.4, 0.7)	0.5 (0.4, 0.7)
Total fat mass, kg	26.4 (21.2, 32.9)	33.4 (26.6, 39)	25 (18.9, 30.4)	21.8 (18.4, 25.1)	29.7 (26, 36.4)	25.5 (21.1, 30.7)
Body mass index, kg/m ²	27.4 (24.1, 31.4)	29.1 (25.1, 33.6)	26.2 (22.8, 30.1)	25.5 (22.7, 28.6)	28.7 (25.4, 32.9)	28.3 (24.6, 32.4)

^aCount (percentage) of categorical variables and median (interquartile range) of continuous variables are presented across race/ethnicity of MEC-APS participants.


<https://doi.org/10.1371/journal.pone.0279932.t001>

total fat mass, the rs79926925 association was attenuated only slightly at $P = 3.93 \times 10^{-7}$ (Beta per allele = 6.15) (S1 Table). In females, the C allele of rs79926925 was most frequent in

a) Overall (N=1787)



b) Males (n=878)



c) Females (n=909)




Fig 1. Manhattan plots of SNP P-values from the visceral fat to abdominal area ratio genome-wide association study in the Multiethnic Cohort-Adiposity Phenotype Study (MEC-APS). The Y-axis shows the negative base ten logarithm of the P-values and the X-axis shows the chromosomes. The genome-wide significance threshold, $P < 5 \times 10^{-8}$, is shown in red: a) Overall (N = 17,87), b) Males (n = 878), c) Females (n = 909).

<https://doi.org/10.1371/journal.pone.0279932.g001>

Japanese Americans (5%), present at low frequency in Native Hawaiians (1.2%), and not observed in African Americans, European Americans, or Latinos (Table 3C). The most significant association across race/ethnicities among women between rs79926925 and %VAT was in Japanese Americans (Beta = 6.73; $P = 5.65 \times 10^{-5}$) with consistent effect estimates and directions of associations in Native Hawaiians (Table 3C). Rs79926925 was not associated with %VAT in males (Beta = 1.58, $P = 0.35$) (S2B and S3B Tables), but the beta was in the same direction. Okinawan Americans were found to have a higher frequency (7%) compared to mainland Japanese (3.5%) for the variant C allele of rs79926926. In women, (Okinawan Americans n = 23 and mainland Japanese Americans n = 54) the magnitude of association with the C allele of rs79926926 was similar in Okinawan Americans (Beta = 4.1, $P = 0.50$) and in mainland Japanese Americans (Beta = 5.5, $P = 0.043$), adjusted for age and sex-specific principal components. Consistent with their greater allele frequency, Okinawan American women also had significantly more %VAT (median = 25.1) compared to mainland Japanese Americans (median = 22.0) ($P = 0.0073$).

Several biomarkers were significantly associated with the lead variant (rs79837492) in expected directions from the sex-combined GWAS (CRP, insulin, SHBG, and triglycerides) and the lead variant (rs2968545) from the male-only GWAS (glucose, HOMA-IR, insulin, and triglycerides), at $P < 0.05$; however, after adjusting for total adiposity, none of the biomarker associations remained statistically significant (Table 4A). Rs2968545 was not significantly associated with any biomarkers in females (S4A Table). The lead variant from the female-only GWAS, rs79926925, was associated with SHBG: The C allele of rs79926925 was associated with a 0.21-fold decrease (Beta = -0.24; $P = 0.028$) in geometric mean for SHBG in females (Table 4C). Rs79926925 was not significantly associated with any biomarkers in males (S4B Table).

The UK Biobank VAT volume data set was comprised of 23,784 participants of white British or Irish ancestry, 211 of Asian ancestry (Indian, Pakistani, or Bangladeshi), 135 of African or Caribbean ancestry, and 973 of other or mixed ancestry. In UK Biobank participants, both rs79837492 (sex-combined Beta = -0.007, $P = 0.38$; male-only Beta = -0.026, $P = 0.019$, female-only Beta = 0.011, $P = 0.34$) and rs2968545 (sex-combined Beta = -0.008, $P = 0.30$; male-only Beta = -0.028, $P = 0.010$, female-only Beta = 0.011, $P = 0.37$) were significantly associated in males, but not in females, with log-transformed MRI-measured VAT volume adjusted for body mass index (BMI), age, sex, and principal components 1–4 (Table 5). The frequency of the effect allele was higher in the UK Biobank compared to MEC-APS for both rs79837492 ((Effect allele frequency) EAF = 0.051 vs. EAF = 0.022, respectively) and rs2968545 (EAF = 0.052 vs. EAF = 0.033, respectively) (Table 5). Consistent with MEC-APS, the allele frequency for males and females was similar for both rs79837492 (male EAF = 0.050 and female EAF = 0.050) and rs2968545 (male EAF = 0.052 and female EAF = 0.050) (Table 5). The variant C allele of rs79926925 was not observed in participants with MRI-measured VAT volume in the UK Biobank.

Four published GWAS of VAT have detected genome-wide significant associations [16, 18–20] (S5 Table). In addition, there have been two GWAS that found genome-wide significant variants using the UK Biobank data, one that explored predicted VAT mass derived from DXA measurements and one MedRxiv preprint that examined MRI-measured VAT mass [21] (S5 Table). There was evidence of replication in MEC-APS ($P < 0.05$) for seven variants of the 115 previously identified genome-wide significant variants: rs113658831




Fig 2. Regional plots of SNP P-values in a ± 200 kb window around rs79837429, rs2968545, and rs79926925. The X-axis shows the chromosome and physical location (Mb), the left Y-axis shows the negative base ten logarithm of the P-values, and the right Y-axis shows recombination activity (cM/Mb) as a blue line. Positions, recombination rates, and gene annotations are according to NCBI's build 37 (hg 19) and the 1000 Genomes Project Phase 3 multiethnic data set: a) Regional plot of rs79837429, b) Regional plot of rs2968545, c) Regional plot of rs79926925.

<https://doi.org/10.1371/journal.pone.0279932.g002>

($P = 0.031$), rs2949785 ($P = 0.010$), rs56398417 ($P = 0.031$), rs10962547 ($P = 0.018$), rs7942037 ($P = 0.0053$), rs3764002 ($P = 0.041$), rs4239060 ($P = 0.020$), and rs1329254 ($P = 0.029$) (S5 Table).

Table 2. Genetic variants associated with the ratio of visceral fat to abdominal area in the MEC-APS ($P < 10^{-7}$).

a) Sex-combined (N = 1787)									
Variant	Chr ^c	Position ^d	Imputed Info score	Ref Allele	Effect Allele	EAF ^e	Beta	SE	P-value
rs79837492 ^{a,b}	2	125201730	0.96	C	T	0.022	-4.76	0.85	2.62x10 ⁻⁸
rs75293929	2	125237347	0.98	A	G	0.022	-4.7	0.86	2.94x10 ⁻⁸
rs77575492	2	125200134	0.96	A	G	0.022	-4.7	0.85	3.12x10 ⁻⁸
rs74805958	2	125216045	0.99	T	C	0.022	-4.66	0.84	3.25x10 ⁻⁸
rs111548554	2	125211775	0.99	A	T	0.022	-4.66	0.84	3.34x10 ⁻⁸
rs76381612	2	125236095	0.98	A	C	0.022	-4.65	0.84	3.37x10 ⁻⁸
rs76377414	2	125208103	1.00	A	C	0.022	-4.66	0.84	3.43x10 ⁻⁸
rs76651976	2	125208020	1.00	A	G	0.022	-4.66	0.84	3.43x10 ⁻⁸
rs75297301	2	125207690	genotyped	T	C	0.022	-4.66	0.84	3.45x10 ⁻⁸
rs111545964	2	125227517	0.98	G	A	0.024	-4.5	0.81	3.70x10 ⁻⁸
rs79269543	2	125194156	0.95	C	T	0.023	-4.63	0.84	4.50x10 ⁻⁸
rs78658619	2	125191084	0.93	T	C	0.023	-4.61	0.85	6.14x10 ⁻⁸
rs2420864	2	125217386	0.99	C	T	0.033	-4.66	0.68	8.10x10 ⁻⁸
rs77575492	2	125216924	0.99	A	G	0.033	-4.66	0.68	8.11x10 ⁻⁸
rs2420858	2	125213719	0.99	G	T	0.033	-4.66	0.68	8.24x10 ⁻⁸
rs2968545	2	125209666	0.99	A	C	0.033	-4.66	0.68	8.38x10 ⁻⁸
b) Male-only (n = 878)									
Variant	Chr ^c	Position ^d	Imputed Info score	Ref Allele	Effect Allele	EAF ^e	Beta	SE	P-value
rs2968545 ^{a,b}	2	125209666	0.99	A	C	0.033	-6.5	1.06	1.09x10 ⁻⁹
rs2420858	2	125213719	0.99	G	T	0.033	-6.65	1.06	1.13x10 ⁻⁹
rs77575492	2	125216924	0.99	A	G	0.033	-6.65	1.06	1.16x10 ⁻⁹
rs2420864	2	125217386	0.99	C	T	0.033	-6.65	1.06	1.17x10 ⁻⁹
rs78658619	2	125191084	0.93	C	T	0.023	-7.2	1.28	2.33x10 ⁻⁸
rs79269543	2	125194156	0.95	C	T	0.024	-7.2	1.26	2.43x10 ⁻⁸
rs79837492	2	125201730	0.96	C	T	0.023	-7.2	1.29	2.70x10 ⁻⁸
rs77575492	2	125200134	0.96	A	G	0.023	-7.1	1.27	3.06x10 ⁻⁸
rs113164486	2	125173963	0.87	G	A	0.024	-7.36	1.33	4.10x10 ⁻⁸
rs75293929 ^{a,c}	2	125237347	0.98	A	G	0.022	-7.03	1.28	4.49x10 ⁻⁸
rs76524201	2	125176877	0.88	A	G	0.024	-7.3	1.32	4.55x10 ⁻⁸
rs75297301	2	125207690	genotyped	T	C	0.023	-7.16	1.26	5.08x10 ⁻⁸
rs76377414	2	125208103	1	A	C	0.023	-6.9	1.26	5.10x10 ⁻⁸
rs76651976	2	125208020	1.00	A	G	0.023	-6.9	1.26	5.10x10 ⁻⁸
rs111545964	2	125227517	0.98	G	A	0.025	-6.7	1.23	5.20x10 ⁻⁸
rs111548554	2	125211775	0.99	A	T	0.023	-6.8	1.26	5.27x10 ⁻⁸
rs74805958	2	125216045	0.99	T	C	0.023	-6.9	1.26	5.51x10 ⁻⁸
rs76381612	2	125236095	0.98	A	C	0.023	-6.9	1.26	6.16x10 ⁻⁸
rs77919433	2	125178343	0.88	C	G	0.024	-7.22	1.26	6.28x10 ⁻⁸
b) Female-only (n = 909)									
SNP	Chr ^c	Position ^d	Imputed Info score	Ref Allele	Effect Allele	EAF ^e	Beta	SE	P-value
rs79926925 ^{a,b}	13	20891618	0.99	T	C	0.013	6.95	1.29	8.15x10 ⁻⁸

^aAdjusted for age, sex, and overall principal components 1–4. ^bFor rs79837492, there were approximately 79 T alleles in the overall MEC-APS population. ^cChr, chromosome. ^dPosition according to NCBI build37. ^eEAF, Effect allele frequency.

^aAdjusted for age, sex, and overall principal components 1–4. ^bFor rs2968545, there were approximately 58 C alleles in self-reported males. ^cChr, chromosome. ^dPosition according to NCBI build37. ^eEAF, Effect allele frequency.

^aAdjusted for age, sex, and overall principal components 1–4. ^bFor rs79926925, there were approximately 24 C alleles in self-reported females. ^cChr, chromosome.

^dPosition according to NCBI build37. ^eEAF, Effect allele frequency.

<https://doi.org/10.1371/journal.pone.0279932.t002>

Table 3. Genetic variants associated with percent visceral fat in the MEC-APS ($P < 10^{-7}$), by race/ethnicity.

a) Sex-combined (N = 1787) ^a																					
Variant	Chr ^b	African American (n = 301)				European American (n = 401)				Japanese American (n = 428)				Latino (n = 372)				Native Hawaiian (n = 285)			
		EAF ^c	Beta	SE	P	EAF ^c	Beta	SE	P	EAF ^c	Beta	SE	P	EAF ^c	Beta	SE	P	EAF ^c	Beta	SE	P
rs79837492	2	0.026	-6.15	1.56	0.00010	0.049	-4.76	1.26	0.00019	-	-	-	-	0.02	-2.62	1.79	0.14	0.011	-7.68	2.97	0.0101
rs75293929	2	0.030	-5.29	1.45	0.00031	0.047	-4.84	1.29	0.00021	-	-	-	-	0.02	-2.91	1.79	0.10	0.011	-7.73	2.88	0.0078
rs77575492	2	0.028	-5.91	1.50	0.00010	0.049	-4.77	1.27	0.00019	-	-	-	-	0.02	-2.56	1.79	0.15	0.011	-7.60	2.98	0.0112
rs74805958	2	0.029	-5.26	1.45	0.00034	0.048	-4.72	1.28	0.00026	-	-	-	-	0.02	-2.92	1.79	0.10	0.010	-7.84	2.89	0.0071
rs111548554	2	0.029	-5.24	1.45	0.00036	0.048	-4.72	1.28	0.00026	-	-	-	-	0.02	-2.92	1.79	0.10	0.010	-7.86	2.90	0.0072
rs76381612	2	0.030	-5.28	1.45	0.00031	0.048	-4.72	1.28	0.00026	-	-	-	-	0.02	-2.92	1.79	0.10	0.011	-7.71	2.86	0.0075
rs76377414	2	0.029	-5.21	1.45	0.00038	0.048	-4.72	1.28	0.00026	-	-	-	-	0.02	-2.92	1.79	0.10	0.010	-7.87	2.90	0.0072
rs76651976	2	0.029	-5.21	1.45	0.00038	0.048	-4.72	1.28	0.00026	-	-	-	-	0.02	-2.92	1.79	0.10	0.010	-7.87	2.90	0.0072
rs75297301	2	0.029	-5.21	1.45	0.00039	0.048	-4.72	1.28	0.00026	-	-	-	-	0.02	-2.92	1.79	0.10	0.010	-7.87	2.90	0.0072
rs111545964	2	0.039	-4.67	1.28	0.00030	0.048	-4.72	1.28	0.00025	-	-	-	-	0.02	-2.63	1.78	0.14	0.011	-7.77	2.88	0.0073
rs79269543	2	0.029	-5.93	1.49	0.00009	0.049	-4.80	1.27	0.00018	-	-	-	-	0.02	-2.35	1.78	0.19	0.012	-7.33	3.00	0.0152
rs78658619	2	0.029	-5.97	1.51	0.00009	0.049	-4.82	1.27	0.00017	-	-	-	-	0.02	-2.26	1.79	0.21	0.012	-7.10	3.00	0.0188
rs2420864	2	0.094	-3.13	0.83	0.00020	0.049	-4.32	1.27	0.00072	-	-	-	-	0.02	-2.19	1.63	0.18	0.011	-7.84	2.89	0.0071
rs77575492	2	0.094	-3.12	0.83	0.00020	0.049	-4.32	1.27	0.00072	-	-	-	-	0.02	-2.19	1.63	0.18	0.011	-7.84	2.89	0.0071
rs2420858	2	0.094	-3.12	0.83	0.00020	0.049	-4.32	1.27	0.00072	-	-	-	-	0.02	-2.19	1.63	0.18	0.011	-7.86	2.90	0.0071
rs2968545	2	0.094	-3.12	0.83	0.00021	0.049	-4.32	1.27	0.00073	-	-	-	-	0.02	-2.19	1.63	0.18	0.011	-7.86	2.90	0.0072
b) Male-only (n = 878) ^a																					
Variant	Chr ^b	African American (n = 126)				European American (n = 207)				Japanese American (n = 216)				Latino (n = 187)				Native Hawaiian (n = 142)			
		EAF ^c	Beta	SE	P	EAF ^c	Beta	SE	P	EAF ^c	Beta	SE	P	EAF ^c	Beta	SE	P	EAF ^c	Beta	SE	P
rs2968545 ^{a,b}	2	0.113	-5.93	1.27	8.6x10 ⁻⁶	0.052	-9.10	1.93	4.69x10 ⁻⁶	-	-	-	-	0.018	3.01	2.81	0.28	0.0035	-11.32	7.72	0.15
rs2420858	2	0.114	-5.91	1.27	9.1x10 ⁻⁶	0.052	-9.11	1.93	4.65x10 ⁻⁶	-	-	-	-	0.018	3.01	2.81	0.29	0.0035	-11.35	7.72	0.14
rs77575492	2	0.114	-5.90	1.27	9.5x10 ⁻⁶	0.052	-9.11	1.93	4.62x10 ⁻⁶	-	-	-	-	0.018	3.01	2.81	0.29	0.0036	-11.37	7.72	0.14
rs2420864	2	0.114	-5.89	1.27	9.6x10 ⁻⁶	0.052	-9.11	1.93	4.62x10 ⁻⁶	-	-	-	-	0.018	3.01	2.81	0.29	0.0036	-11.37	7.72	0.14
rs78658619	2	0.047	-7.26	2.08	0.0006809	0.052	-9.12	1.94	4.90x10 ⁻⁶	-	-	-	-	0.017	-3.80	2.93	0.20	0.0042	-11.27	7.70	0.15
rs79269543	2	0.048	-7.12	2.05	0.0006981	0.052	-9.11	1.94	4.85x10 ⁻⁶	-	-	-	-	0.018	-3.65	2.91	0.21	0.0041	-11.32	7.72	0.15
rs79837492	2	0.043	-7.70	2.18	0.0005728	0.052	-9.11	1.94	4.77x10 ⁻⁶	-	-	-	-	0.018	-3.37	2.86	0.24	0.0038	-11.35	7.73	0.14
rs77575492	2	0.047	-7.11	2.07	0.0008152	0.052	-9.11	1.94	4.79x10 ⁻⁶	-	-	-	-	0.018	-3.44	2.87	0.23	0.0039	-11.36	7.73	0.14
rs113164486	2	0.043	-8.20	2.27	0.0004323	0.052	-8.75	1.98	1.66x10 ⁻⁶	-	-	-	-	0.018	-4.12	3.14	0.19	0.0043	-11.18	7.73	0.15
rs75293929	2	0.047	-6.67	2.06	0.0015253	0.049	-9.44	1.97	3.14x10 ⁻⁶	-	-	-	-	0.018	-3.02	2.81	0.28	0.0034	-12.00	8.10	0.14
rs76524201	2	0.044	-8.06	2.24	0.0004630	0.052	-8.69	1.98	1.81x10 ⁻⁶	-	-	-	-	0.018	-4.07	3.10	0.19	0.0041	-11.40	7.74	0.14
rs75297301	2	0.046	-6.86	2.06	0.0011554	0.052	-9.10	1.93	4.73x10 ⁻⁶	-	-	-	-	0.018	-3.02	2.81	0.28	0.0035	-11.32	7.72	0.15
rs76377414	2	0.046	-6.86	2.06	0.0011629	0.052	-9.10	1.93	4.72x10 ⁻⁶	-	-	-	-	0.018	-3.02	2.81	0.28	0.0035	-11.32	7.72	0.15
rs76651976	2	0.046	-6.86	2.06	0.0011607	0.052	-9.10	1.93	4.73x10 ⁻⁶	-	-	-	-	0.018	-3.02	2.81	0.28	0.0035	-11.32	7.72	0.15
rs111545964	2	0.057	-6.33	1.89	0.0011162	0.052	-9.11	1.93	4.59x10 ⁻⁶	-	-	-	-	0.018	-2.78	2.81	0.32	0.0036	-11.39	7.73	0.14
rs111548554	2	0.046	-6.83	2.06	0.0012208	0.052	-9.10	1.93	4.70x10 ⁻⁶	-	-	-	-	0.018	-3.02	2.81	0.28	0.0035	-11.34	7.72	0.14
rs74805958	2	0.046	-6.78	2.06	0.0013164	0.052	-9.11	1.93	4.65x10 ⁻⁶	-	-	-	-	0.018	-3.02	2.81	0.28	0.0035	-11.37	7.72	0.14
rs76381612	2	0.047	-6.66	2.06	0.0015556	0.052	-9.11	1.93	4.54x10 ⁻⁶	-	-	-	-	0.018	-3.02	2.81	0.28	0.0036	-11.43	7.73	0.14
rs77919433	2	0.045	-8.01	2.22	0.0004510	0.052	-8.63	2.00	2.4x10 ⁻⁵	-	-	-	-	0.018	-4.04	3.09	0.19	0.0041	-11.36	7.73	0.14
(Continued)																					

(Continued)

Table 3. (Continued)

b) Female-only (n = 909) ^a		African American (n = 175)				European American (n = 154)				Japanese American (n = 201)				Latino (n = 185)				Native Hawaiian (n = 194)			
Variant	Chr ^b	EAF ^c	Beta	SE	P	EAF ^c	Beta	SE	P	EAF ^c	Beta	SE	P	EAF ^c	Beta	SE	P	EAF ^c	Beta	SE	P
rs79926925	13	-	-	-	-	-	-	-	-	0.048	6.37	1.21	5.65x10 ⁻⁵	-	-	-	-	0.012	6.68	3.26	0.042

^aAdjusted for age, sex, and race/ethnic specific principal components 1–4.^bChr, chromosome.^cEAF, Effect allele frequency.<https://doi.org/10.1371/journal.pone.0279932.t003>

Table 4. The association between lead significant and suggestive variants associated with percent visceral fat and obesity-related biomarkers in the MEC-APS, adjusted for total fat mass.

a) Sex-combined					
Variant	Biomarker	N	Beta^{a,b}	SE	P-value
rs79837492	HDL (mg/dL)	1813	-0.015	0.053	0.77
	LDL (mg/dL)	1808	-0.056	0.050	0.26
	Total Cholesterol (mg/dL)	1814	-0.033	0.034	0.33
	Glucose (mg/dL)	1812	-0.033	0.029	0.25
	HOMA-beta (%)	1801	-0.037	0.103	0.72
	HOMA-IR	1814	-0.033	0.086	0.70
	CRP (mg/L)	1814	-0.318	0.214	0.14
	Insulin (microU/mL)	1814	-0.055	0.077	0.50
	SHBG (nmol/L)	1807	0.086	0.061	0.16
	Triglycerides (mg/dL)	1814	-0.082	0.056	0.15
	ALT (U/L)	1814	-0.067	0.061	0.27
b) Males					
Variant	Biomarker	N	Beta^{a,b}	SE	P-value
rs2968545	HDL (mg/dL)	897	-0.003	0.060	0.96
	LDL (mg/dL)	894	-0.037	0.060	0.53
	Total Cholesterol (mg/dL)	898	-0.033	0.041	0.43
	Glucose (mg/dL)	896	-0.045	0.032	0.16
	HOMA-beta (%)	894	-0.102	0.117	0.38
	HOMA-IR	896	-0.119	0.095	0.21
	CRP (mg/L)	898	-0.209	0.251	0.40
	Insulin (microU/mL)	898	-0.126	0.090	0.16
	SHBG (nmol/L)	895	0.056	0.063	0.38
	Triglycerides (mg/dL)	898	-0.077	0.065	0.24
	ALT (U/L)	898	-0.030	0.069	0.66
c) Females					
Variant	Biomarker	N	Beta^b	SE	P-value
rs79926925	HDL (mg/dL)	916	-0.026	0.091	0.78
	LDL (mg/dL)	914	-0.055	0.079	0.49
	Total Cholesterol (mg/dL)	916	-0.047	0.053	0.37
	Glucose (mg/dL)	916	0.055	0.49	0.26
	HOMA-beta (%)	907	0.049	0.17	0.77
	HOMA-IR	916	0.23	0.15	0.12
	CRP (mg/L)	916	0.47	0.35	0.18
	Insulin (microU/mL)	916	0.19	0.13	0.13
	SHBG (nmol/L)	912	-0.24	0.11	0.028
	Triglycerides (mg/dL)	916	0.057	0.092	0.54
	ALT (U/L)	916	-0.006	0.10	0.96

^aAdjusted for age, sex, principal components 1–4, and total fat mass (kg). ^bLog unit change per allele increase.

^aAdjusted for age, sex specific principal components 1–4, and total fat mass (kg). ^bLog unit change per allele increase.

<https://doi.org/10.1371/journal.pone.0279932.t004>

Discussion

In our GWAS of the %VAT in a racially/ethnically diverse population, we observed a genome-wide significant signal on chromosome 2q14.3 (lead variant rs79837492) in the sex-combined

Table 5. The association between lead significant variants associated with visceral fat volume (cm³) in the UK Biobank^a.

Variant	Chr	Sex-combined (N = 23,699)				Male (n = 11,524)				Female (n = 12,175)			
		EAF	Beta ^b	SE	P	EAF	Beta ^b	SE	P	EAF	Beta ^b	SE	P
rs79837492	2	0.051	-0.007	0.007	0.38	0.050	-0.026	0.011	0.019	0.050	0.011	0.012	0.34
rs2968545	2	0.052	-0.008	0.008	0.30	0.051	-0.028	0.011	0.010	0.050	0.011	0.012	0.37

^aadjusted for body mass index, age, sex, and principal components 1–4.^blog unit change per allele increase.<https://doi.org/10.1371/journal.pone.0279932.t005>

analysis, the same genome-wide significant signal on chromosome 2q14.3 (lead variant rs2968545) in the male-only GWAS, and a suggestive variant (rs79926925) on chromosome 13q12.11 in the female-only GWAS. The genome-wide significant signal on chromosome 2q14.3 is located in intron 5 of *CNTNAP5*. The suggestive variant, rs79926925 on chromosome 13q12.11 is located in an intergenic region between *GJB6* and *CRYL1*. Both rs79837492 and rs2968545 were associated with a decrease in mean %VAT; rs79837492 was significantly associated with CPR, SHBG, and triglycerides, and rs2968545 was significantly associated with glucose, HOMA-IR, insulin, and triglycerides at $P = 0.05$ in MEC-APS without adjustment for total adiposity, but neither variant was significantly associated with the obesity-related biomarkers after total adiposity adjustment. The association for both rs79837492 and rs2968545 with %VAT replicated at $P = 0.05$ in the UK Biobank. Rs79926925 was associated with an increase in mean %VAT and a significant decrease in mean SHBG blood levels, and was more common in Okinawan Americans than mainland Japanese Americans.

Since rs79837492 and rs2968545 are intronic and rs79926925 is in an intergenic region, these variants may function through mechanisms that regulate transcriptional activity. There were no eQTLs for either variant when querying the GTEx Portal [38]. *CNTNAP5* is a large gene (~1M bases) that is part of the Caspr family, a family of genes that are involved in cell contacts and communication in the nervous system [39]. Familial deletions, GWAS, and Multivariate and Collapsing (CMC) burden tests, in *CNTNAP5* have mainly found associations with atypical neurodevelopment and intellectual disability [40–43]. However, a genetic variant (rs314944) just downstream of *CNTNAP5* was found to be moderately negatively associated with abdominal visceral adiposity in a Korean study ($P = 4.25 \times 10^{-5}$), and whole blood gene expression of *CNTNAP5* was reported to be reduced after bariatric surgery in patients with type 2 diabetes [19, 44]. Rs79926925 was only present in Japanese American and Native Hawaiian MEC-APS participants, and is located in an intergenic region between *GJB6* and *CRYL1*. *CRYL1* is part of the uronate cycle, which functions as an alternative glucose metabolic pathway, catabolizing 5% of daily glucose [45]. *CRYL1* requires NAD(H) as a coenzyme to catalyze the dehydrogenation of L-gulonate into dehydro-L-gulonate [45]. The variant rs7989332 in *CRYL1* was found to interact with rs6455128 in *KHDRBS2* (KH domain containing, RNA binding, signal transduction associated 2) and be protective against Alzheimer's Disease [46]. More recently, bioinformatics analysis has shown that *CRYL1* is a shared susceptibility gene between late-stage hepatocellular carcinoma and high HBA1c, and that the amount of *CRYL1* is inversely related to tumor stage [47]. Additionally, experiments in rabbits show that *CRYL1* is downregulated in skeletal muscle cells of obese, but not normal weight animals [48].

Recent multiethnic GWAS have found it beneficial, in a multiethnic population, to conduct a joint GWAS, compared to meta-analyzing separate GWAS stratified by race/ethnicity [49, 50]. Wojcik and colleagues (2019) showed that a joint GWAS increases power compared to a meta-analysis approach, while maintaining the type I error rate [49]. In MEC, the first four

principal components are able to differentiate the five different race/ethnicities (African American, European American, Japanese American, Latino, and Native Hawaiian). Wang and colleagues (2010) showed that African American, European American, and Japanese American MEC participants separate on principal components 1 and 2, Latinos separate on principal component 3, and Native Hawaiians separate on principal component 4 [51]. The first four principal components only adjust for some intra-population structure (e.g. mainland Japanese vs. Okinawan) associations between significant or suggestive genetic variants. However, %VAT was also examined in race/ethnicity specific models that can account for intra-population structure by adjusting for race/ethnicity specific principal components. Related individuals (20 pairs of first degree relatives) were not removed from the GWAS because relatedness was limited to pairs of individuals who did not form related subpopulations within the data set. When relatedness does not lead to the creation of subpopulations in a data set, retaining related individuals does not cause long-range LD leading to misleading associations or loss of power [27, 52, 53].

Among Japanese Americans in the MEC, this is the first time Okinawan Americans have been distinguished from mainland Japanese Americans. Historically, Okinawa had the highest life expectancy from birth among all Japanese prefectures with low rates of chronic disease [54]. Today Okinawa have some of the highest chronic disease rates in Japan, believed to be due in part to a Westernized lifestyle/diet introduced by the US military presence since World War II [55]. Our novel findings in Okinawan Americans may imply unidentified gene-environment factors that warrant further investigation.

Rs79837492 and rs2968545 were genome-wide significant ($P = 5 \times 10^{-8}$) in the sex-combined and male-only MEC-APS GWAS and significant at $P = 0.05$ in the male-only UK Biobank replication. Neither rs79837492 nor rs2968545 were genome-wide significant in the female-only MEC-APS GWAS or the UK Biobank female-only replication. While these lead MEC-APS variants replicated in the UK Biobank, there are some study differences that could explain study-dependent strengths of association. First, MEC-APS examined VAT as a proportion of abdominal area, whereas the UK Biobank provided data on VAT volume as an absolute measure, and second, because the EAF for rs79837492 and rs2968545 differ between studies, it is also possible that the white and black participants' ancestry may differ between studies. The variant rs79926925 was not found in UK Biobank participants with abdominal MRI imaging, most likely because rs79926925 was not observed in whites and only present in Japanese Americans and Native Hawaiians in MEC-APS, and the UK Biobank MRI imaging study selected mainly for participants of white British and Irish ancestry [35].

Of the 115 previously identified genome-wide significant variants with VAT outcomes, only seven replicated in MEC-APS ($P < 0.05$) [16, 18–20]. Reasons for non-replication of 108 previously identified genome-wide significant variants may be attributed to different racial/ethnic compositions of the study population, dissimilar VAT outcomes (i.e. absolute VAT, VAT adjusted for BMI, VAT/SAT, and predicted VAT), and use of CT or DXA (VAT measured by DXA only approximates VAT measured by the gold-standard MRI) for abdominal imaging [56].

To our knowledge, this is the first study to conduct GWAS for %VAT and one of the few studies to examine the genetics of visceral fat in a multiethnic population. Additional strengths of our study include the use of the MEGA^{EX} genotyping array, which provides comprehensive coverage of variants for a multiethnic population and the use of MRI to measure abdominal adiposity, which is the gold standard method for measuring visceral fat. The study population, however, was modest in size ($N = 1,787$) and, thus, statistical power to detect weak to moderate effects was limited. A power analysis with 1,787 subjects (population mean = 24.0, standard deviation = 8.3) shows that a GWAS would have $> 80\%$ power to detect a variant with 2% change in mean %VAT with a MAF > 0.15 (at $P = 5 \times 10^{-8}$) [57].

In summary, we found a significant signal on chromosome 2q14.3 in the sex-combined (lead variant rs79837492) and male-only (lead variant rs2968545) GWAS of %VAT, and one suggestive variant (rs79926925) in the female-only GWAS of %VAT in MEC-APS. The negatively associated lead variants (rs79837492 and rs2968545) were most common in European Americans and African Americans and the positively associated lead variant (rs79926925) was most common in Japanese Americans: this was all consistent with the racial/ethnic %VAT differences. The variant allele of rs79926925, associated with a mean increase in %VAT in women, also showed an association with decreased blood levels of SHBG. These findings should be considered as preliminary and they require replication in larger studies using gold-standard methods (MRI or CT) to measure visceral fat.

Supporting information

S1 Fig. Q-Q plot of SNP P-values from the ratio of visceral fat to abdominal area GWAS, all MEC-APS participants, and by male and female MEC-APS participants. The Y-axis shows the negative base ten logarithm of the observed p-values and the X-axis shows the negative base ten logarithm of the expected p-values.

(DOCX)

S2 Fig. Principal component plot 2 vs. 1 for 432 Japanese Americans in the Multiethnic Cohort-Adiposity Phenotype Study (MEC-APS). The vertical line demarcates separation between Japanese Americans and part-Japanese Americans. The top horizontal line demarcates separation between Okinawan Americans and part-Okinawan & part-mainland Japanese Americans and the bottom horizontal line demarcates separation between part-Okinawan & part-mainland Japanese Americans and mainland-Japanese Americans.

(DOCX)

S1 Table. Lead variants ($P < 10^{-7}$) from the visceral fat to abdominal area ratio GWAS further adjusted for total fat mass (kg).

(XLSX)

S2 Table. Genetic variants with $P < 10^{-7}$ from the self-reported male and female GWAS on the visceral fat to abdominal area ratio, in the other sex: a) Female ($n = 909$), b) Male ($n = 878$).

(XLSX)

S3 Table. Genetic variants with $P < 10^{-7}$ from the self-reported male and female GWAS on the visceral fat to abdominal area ratio, in the other sex by race/ethnicity.

(XLSX)

S4 Table. The association between lead significant and suggestive variants associated with the visceral fat to abdominal area ratio and obesity-related biomarkers in the MEC-APS, in the other sex.

(XLSX)

S5 Table. Replication in the Multiethnic Cohort-Adiposity Phenotype Study (MEC-APS) of previously novel significant ($P < 5 \times 10^{-8}$) variant associations with visceral adipose tissue and the ratio of visceral adipose tissue to subcutaneous adipose tissue.

(XLSX)

Author Contributions

Conceptualization: Samantha A. Streicher, Iona Cheng, Loïc Le Marchand.

Data curation: Unhee Lim, Xin Sheng, Victor Hom, Lucy Xia, Loreall Pooler, John Shepherd, Thomas Ernst, Steven Buchthal, Adrian A. Franke, Lynne R. Wilkens, Daniel O. Stram, Iona Cheng, Loïc Le Marchand.

Formal analysis: Samantha A. Streicher.

Funding acquisition: Lynne R. Wilkens, Christopher A. Haiman.

Methodology: Samantha A. Streicher, S. Lani Park, Yuqing Li.

Supervision: Unhee Lim, Lynne R. Wilkens, Christopher A. Haiman, Iona Cheng, Loïc Le Marchand.

Validation: Samantha A. Streicher, Christopher A. Haiman.

Visualization: Lenora W. M. Loo, Maarit Tiirikainen, Daniel O. Stram.

Writing – original draft: Samantha A. Streicher.

Writing – review & editing: Samantha A. Streicher, Unhee Lim, S. Lani Park, Yuqing Li, Xin Sheng, Victor Hom, Lucy Xia, Loreall Pooler, John Shepherd, Lenora W. M. Loo, Thomas Ernst, Steven Buchthal, Adrian A. Franke, Maarit Tiirikainen, Lynne R. Wilkens, Christopher A. Haiman, Daniel O. Stram, Iona Cheng, Loïc Le Marchand.

References

1. Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N Engl J Med*. 2017; 377:13–27. <https://doi.org/10.1056/NEJMoa1614362> PMID: 28604169
2. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body Fatness and Cancer—Viewpoint of the IARC Working Group. *N Engl J Med*. 2016; 375:794–8. <https://doi.org/10.1056/NEJMs1606602> PMID: 27557308
3. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. *Circulation*. 2007; 116:39–48. <https://doi.org/10.1161/CIRCULATIONAHA.106.675355> PMID: 17576866
4. Vega GL, Adams-Huet B, Peshock R, Willett D, Shah B, Grundy SM. Influence of body fat content and distribution on variation in metabolic risk. *J Clin Endocrinol Metab*. 2006; 91:4459–66. <https://doi.org/10.1210/jc.2006-0814> PMID: 16926254
5. Le Marchand L, Wilkens LR, Castelfranco AM, Monroe KR, Kristal BS, Cheng I, et al. Circulating biomarker score for visceral fat and risks of incident colorectal and postmenopausal breast cancer: The Multiethnic Cohort Adiposity Phenotype Study. *Cancer Epidemiol Biomarkers Prev*. 2020; 29:966–73. <https://doi.org/10.1158/1055-9965.EPI-19-1469> PMID: 32132150
6. Maskarinec G, Raquinio P, Kristal BS, Franke AA, Buchthal SD, Ernst TM, et al. Body Fat Distribution, Glucose Metabolism, and Diabetes Status among Older Adults: The Multiethnic Cohort Adiposity Phenotype Study. *J Epidemiol*. 2021. <https://doi.org/10.2188/jea.JE20200538> PMID: 33642515
7. Hursting SD, Lashinger LM, Wheatley KW, Rogers CJ, Colbert LH, Nunez NP, et al. Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link. *Best Pract Res Clin Endocrinol Metab*. 2008; 22:659–69. <https://doi.org/10.1016/j.beem.2008.08.009> PMID: 18971125
8. Perseghin G, Calori G, Lattuada G, Ragogna F, Dugnani E, Garancini MP, et al. Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. *Acta Diabetol*. 2012; 49:421–8. <https://doi.org/10.1007/s00592-011-0361-2> PMID: 22215126
9. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. *Obes Rev*. 2010; 11:11–8. <https://doi.org/10.1111/j.1467-789X.2009.00623.x> PMID: 19656312
10. Kabir M, Catalano KJ, Ananthnarayan S, Kim SP, Van Citters GW, Dea MK, et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. *Am J Physiol Endocrinol Metab*. 2005; 288:E454–61. <https://doi.org/10.1152/ajpendo.00203.2004> PMID: 15522994
11. Neeland IJ, Grundy SM, Li X, Adams-Huet B, Vega GL. Comparison of visceral fat mass measurement by dual-X-ray absorptiometry and magnetic resonance imaging in a multiethnic cohort: the

- Dallas Heart Study. *Nutr Diabetes*. 2016; 6:e221. <https://doi.org/10.1038/nutd.2016.28> PMID: 27428873
12. Lim U, Monroe KR, Buchthal S, Fan B, Cheng I, Kristal BS, et al. Propensity for intra-abdominal and hepatic adiposity varies among ethnic groups. *Gastroenterology*. 2019; 156:966–75. <https://doi.org/10.1053/j.gastro.2018.11.021> PMID: 30445012
 13. Gavin KM, Bessesen DH. Sex Differences in Adipose Tissue Function. *Endocrinol Metab Clin North Am*. 2020; 49:215–28. <https://doi.org/10.1016/j.ecl.2020.02.008> PMID: 32418585
 14. Zillikens MC, Yazdanpanah M, Pardo LM, Rivadeneira F, Aulchenko YS, Oostra BA, et al. Sex-specific genetic effects influence variation in body composition. *Diabetologia*. 2008; 51:2233–41. <https://doi.org/10.1007/s00125-008-1163-0> PMID: 18839131
 15. Lim U, Ernst T, Buchthal SD, Latch M, Albright CL, Wilkens LR, et al. Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index. *Nutr Diabetes*. 2011; 1:e6. <https://doi.org/10.1038/nutd.2011.2> PMID: 23449381
 16. Fox CS, Liu Y, White CC, Feitosa M, Smith AV, Heard-Costa N, et al. Genome-wide association for abdominal subcutaneous and visceral adipose reveals a novel locus for visceral fat in women. *PLoS Genet*. 2012; 8:e1002695. <https://doi.org/10.1371/journal.pgen.1002695> PMID: 22589738
 17. Sung YJ, Perusse L, Sarzynski MA, Fornage M, Sidney S, Sternfeld B, et al. Genome-wide association studies suggest sex-specific loci associated with abdominal and visceral fat. *Int J Obes (Lond)*. 2016; 40:662–74. <https://doi.org/10.1038/ijo.2015.217> PMID: 26480920
 18. Chu AY, Deng X, Fisher VA, Drong A, Zhang Y, Feitosa MF, et al. Multiethnic genome-wide meta-analysis of ectopic fat depots identifies loci associated with adipocyte development and differentiation. *Nat Genet*. 2017; 49:125–30. <https://doi.org/10.1038/ng.3738> PMID: 27918534
 19. Hong JT, Cho YS. Identification of genetic loci associated with abdominal visceral adiposity in Korean populations. *Genes & Genomics*. 2017; 39:541–8.
 20. Gao C, Langeveld CD, Ziegler JT, Taylor KD, Norris JM, Chen YI, et al. Genome-wide study of subcutaneous and visceral adipose tissue reveals novel sex-specific adiposity loci in Mexican Americans. *Obesity (Silver Spring)*. 2018; 26:202–12. <https://doi.org/10.1002/oby.22074> PMID: 29178545
 21. Karlsson T, Rask-Andersen M, Pan G, Hoglund J, Wadelius C, Ek WE, et al. Contribution of genetics to visceral adiposity and its relation to cardiovascular and metabolic disease. *Nat Med*. 2019; 25:1390–5. <https://doi.org/10.1038/s41591-019-0563-7> PMID: 31501611
 22. Kolonel L, Henderson B, Hankin J, Nomura A, Wilkens L, Pike M, et al. A multiethnic cohort in Hawaii and Los Angeles: Baseline characteristics. *American Journal of Epidemiology*. 2000; 151:346–57. <https://doi.org/10.1093/oxfordjournals.aje.a010213> PMID: 10695593
 23. Park SL, Li Y, Sheng X, Hom V, Xia L, Zhao K, et al. Genome-wide association study of liver fat: The multiethnic cohort adiposity phenotype study. *Hepatol Commun*. 2020; 4:1112–23. <https://doi.org/10.1002/hep4.1533> PMID: 32766472
 24. Bien SA, Wojcik GL, Zubair N, Gignoux CR, Martin AR, Kocarnik JM, et al. Strategies for enriching variant coverage in candidate disease loci on a multiethnic genotyping array. *PLoS One*. 2016; 11:e0167758. <https://doi.org/10.1371/journal.pone.0167758> PMID: 27973554
 25. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. *Nature*. 2012; 491:56–65. <https://doi.org/10.1038/nature11632> PMID: 23128226
 26. McCarthy S, Das S, Kretschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet*. 2016; 48:1279–83. <https://doi.org/10.1038/ng.3643> PMID: 27548312
 27. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet*. 2006; 38:904–9. <https://doi.org/10.1038/ng1847> PMID: 16862161
 28. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985; 28:412–9.
 29. Mojiminiyi OA, Abdella NA. Effect of homeostasis model assessment computational method on the definition and associations of insulin resistance. *Clin Chem Lab Med*. 2010; 48:1629–34. <https://doi.org/10.1515/CCLM.2010.303> PMID: 20704534
 30. Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clinical Chemistry*. 1972; 18:499–502. PMID: 4337382
 31. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015; 12:e1001779. <https://doi.org/10.1371/journal.pmed.1001779> PMID: 25826379

32. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018; 562:203–9. <https://doi.org/10.1038/s41586-018-0579-z> PMID: 30305743
33. Linge J, Borga M, West J, Tuthill T, Miller MR, Dumitriu A, et al. Body Composition Profiling in the UK Biobank Imaging Study. *Obesity (Silver Spring)*. 2018; 26:1785–95. <https://doi.org/10.1002/oby.22210> PMID: 29785727
34. Consortium UK, Walter K, Min JL, Huang J, Crooks L, Memari Y, et al. The UK10K project identifies rare variants in health and disease. *Nature*. 2015; 526:82–90. <https://doi.org/10.1038/nature14962> PMID: 26367797
35. Littlejohns TJ, Holliday J, Gibson LM, Garratt S, Oesingmann N, Alfaro-Almagro F, et al. The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. *Nat Commun*. 2020; 11:2624.
36. Price AL, Zaitlen NA, Reich D, Patterson N. New approaches to population stratification in genome-wide association studies. *Nat Rev Genet*. 2010; 11:459–63. <https://doi.org/10.1038/nrg2813> PMID: 20548291
37. Nishiyama T, Kishino H, Suzuki S, Ando R, Niimura H, Uemura H, et al. Detailed analysis of Japanese population substructure with a focus on the southwest islands of Japan. *PLoS One*. 2012; 7:e35000. <https://doi.org/10.1371/journal.pone.0035000> PMID: 22509376
38. The GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science*. 2020; 369:318–1330
39. Traut W, Weichenhan D, Himmelbauer H, Winking H. New members of the neuroligin superfamily: multiple rodent homologues of the human CASPR5 gene. *Mamm Genome*. 2006; 17:723–31. <https://doi.org/10.1007/s00335-005-0157-1> PMID: 16845472
40. Djurovic S, Gustafsson O, Mattingsdal M, Athanasiu L, Bjella T, Tesli M, et al. A genome-wide association study of bipolar disorder in Norwegian individuals, followed by replication in Icelandic sample. *J Affect Disord*. 2010; 126:312–6. <https://doi.org/10.1016/j.jad.2010.04.007> PMID: 20451256
41. Aleo S, Milani D, Pansa A, Marchisio P, Gueneri S, Silipigni R. Autism spectrum disorder and intellectual disability in an inherited 2q14.3 micro-deletion involving CNTNAP5. *Am J Med Genet A*. 2020; 182:3071–3. <https://doi.org/10.1002/ajmg.a.61881> PMID: 32975021
42. Ludington EG, Yu S, Bae HA, Barnett CP. Novel de novo 2q14.3 deletion disrupting CNTNAP5 in a girl with intellectual impairment, thin corpus callosum, and microcephaly. *Am J Med Genet A*. 2020; 182:1824–8. <https://doi.org/10.1002/ajmg.a.61592> PMID: 32329157
43. Zhang Y, Li M, Wang Q, Hsu JS, Deng W, Ma X, et al. A joint study of whole exome sequencing and structural MRI analysis in major depressive disorder. *Psychol Med*. 2020; 50:384–95. <https://doi.org/10.1017/S0033291719000072> PMID: 30722798
44. Berisha SZ, Serre D, Schauer P, Kashyap SR, Smith JD. Changes in whole blood gene expression in obese subjects with type 2 diabetes following bariatric surgery: a pilot study. *PLoS One*. 2011; 6: e16729. <https://doi.org/10.1371/journal.pone.0016729> PMID: 21423737
45. O'Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. *Nucleic Acids Res*. 2016; 44:D733–45.
46. Gusareva ES, Carrasquillo MM, Bellenguez C, Cuyvers E, Colon S, Graff-Radford NR, et al. Genome-wide association interaction analysis for Alzheimer's disease. *Neurobiol Aging*. 2014; 35:2436–43. <https://doi.org/10.1016/j.neurobiolaging.2014.05.014> PMID: 24958192
47. Bi Y, Yin B, Fan G. Identification of metabolism genes related to hepatocarcinogenesis and progression in type 2 diabetes mellitus via co-expression networks analysis. *Hereditas*. 2021; 158:14–24. <https://doi.org/10.1186/s41065-021-00177-x> PMID: 33865459
48. Li Y, Wang J, Elzo MA, Gan M, Tang T, Shao J, et al. Multi-Omics Analysis of Key microRNA-mRNA Metabolic Regulatory Networks in Skeletal Muscle of Obese Rabbits. *Int J Mol Sci*. 2021; 22:4204–23. <https://doi.org/10.3390/ijms22084204> PMID: 33921578
49. Wojcik GL, Graff M, Nishimura KK, Tao R, Haessler J, Gignoux CR, et al. Genetic analyses of diverse populations improves discovery for complex traits. *Nature*. 2019; 570:514–8. <https://doi.org/10.1038/s41586-019-1310-4> PMID: 31217584
50. Medina-Gomez C, Felix JF, Estrada K, Peters MJ, Herrera L, Kruijthof CJ, et al. Challenges in conducting genome-wide association studies in highly admixed multi-ethnic populations: the Generation R Study. *Eur J Epidemiol*. 2015; 30:317–30. <https://doi.org/10.1007/s10654-015-9998-4> PMID: 25762173
51. Wang H, Haiman CA, Kolonel LN, Henderson BE, Wilkens LR, Le Marchand L, et al. Self-reported ethnicity, genetic structure and the impact of population stratification in a multiethnic study. *Hum Genet*. 2010; 128:165–77. <https://doi.org/10.1007/s00439-010-0841-4> PMID: 20499252

52. Sesia M, Bates S, Candes E, Marchini J, Sabatti C. False discovery rate control in genome-wide association studies with population structure. *Proc Natl Acad Sci U S A*. 2021;118. <https://doi.org/10.1073/pnas.2105841118> PMID: 34580220
53. Visscher PM, Andrew T, Nyholt DR. Genome-wide association studies of quantitative traits with related individuals: little (power) lost but much to be gained. *Eur J Hum Genet*. 2008; 16:387–90. <https://doi.org/10.1038/sj.ejhg.5201990> PMID: 18183040
54. Bendjilali N, Hsueh WC, He Q, Willcox DC, Nievergelt CM, Donlon TA, et al. Who are the Okinawans? Ancestry, genome diversity, and implications for the genetic study of human longevity from a geographically isolated population. *J Gerontol A Biol Sci Med Sci*. 2014; 69:1474–84. <https://doi.org/10.1093/gerona/glt203> PMID: 24444611
55. Miyagi S, Iwama N, Kawabata T, Hasegawa K. Longevity and diet in Okinawa, Japan: The past, present and future. *Asia-Pacific Journal of Public Health*. 2003; 15:S3–S9. <https://doi.org/10.1177/101053950301500S03> PMID: 18924533
56. Maskarinec G, Shvetsov YB, Wong M, Garber A, Monroe K, Ernst T, et al. Subcutaneous and Visceral Fat Assessment by DXA and MRI in Older Adults and Children. *Obesity (Silver Spring)*. 2022; 30:920–30. <https://doi.org/10.1002/oby.23381> PMID: 35253409
57. QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies [Internet]. 2006. Available from: <http://hydra.usc.edu/gxe>.